Latest news with #KetanPatel
BBC News
7 hours ago
- BBC News
Beccles family pay tribute to son who died in Beccles river
The family of a teenage boy who died in a river have described their loss as "unimaginable" in a tribute posted on their behalf by a community tribute to Nischay Patel, released by Beccles town councillor Tarek Lahin, said the boys' parents were "deeply grateful" to the emergency services and thanked them for their "swift and compassionate response during this incredibly painful time".Crews were called to Beccles Quay in Suffolk when Nischay failed to resurface after entering the River Waveney on Wednesday body of the year nine Sir John Leman High School pupil was later found by search teams. Ketan and Praptiben Patel, who own a newsagents in Beccles, said in the Facebook tribute: "This loss is unimaginable, and as we grieve, we hold close the love of our friends, family, and customers. "Your compassion has touched our hearts more deeply than words can express."Our heartfelt thanks also go out to the wonderful people of Beccles and those from across the country who have shown us so much kindness, love, and support."Flowers and tributes have been left at Beccles Quay and outside the family's described how those "thoughtful gestures" had brought "immense comfort". The family's statement continued: "To everyone who has supported our family -particularly the emergency services and those who went above and beyond - please accept our sincerest gratitude. "As we take time to process this tragedy, we kindly ask for privacy and space, knowing your continued support surrounds us."They added their son's funeral details would be shared with the local community. They invited people to join them in honouring his life. An online fund set up by two women who knew Nischay and his family raised £8,000 in 24 Bird and Layla Eales set up the appeal to help his family cover any lost income and funeral costs. The remainder will be used for a memorial bench and for life-saving equipment at the riverside. Follow Suffolk news on BBC Sounds, Facebook, Instagram and X.
Daily Mail
11 hours ago
- Daily Mail
BREAKING NEWS Parents pay tribute to 14-year-old boy who died swimming in river after going to play with his twin
The grieving parents of a 14-year-old schoolboy who died whilst swimming in a Suffolk river have paid tribute to him as they described their 'unimaginable loss'. Nishcay Patel was swimming in Beccles Quay near Fen Lane with friends and his teenage brother when the incident occurred at around 7.30pm on Wednesday. He entered the River Waveney while playing with his twin brother Niyam, but failed to resurface. Police and emergency services rushed to the scene as onlookers desperately tried to help the group of youngsters. But despite their best efforts, Nishcay, named locally, tragically died at the scene. His parents Ketan and Prabtiben Patel, who own a newsagents in Beccles, shared a heartbreaking statement in which they described the loss of their son as 'unimaginable'. They said: 'We are deeply grateful to the Police, Suffolk Fire & Rescue Service, East of England Ambulance Service, and HM Coastguard for their swift and compassionate response during this incredibly painful time. 'Our heartfelt thanks also go out to the wonderful people of Beccles and those from across the country who have shown us so much kindness, love, and support. 'The outpouring of sympathy—from kind words and beautiful flowers to thoughtful gestures—has brought immense comfort to our family. 'We would especially like to thank Sir John Leman High School, Thirst Youth Hub, the Beccles Community UK Facebook page, and the local newspapers for their continued support and compassion. 'This loss is unimaginable, and as we grieve, we hold close the love of our friends, family, and customers. 'Your compassion has touched our hearts more deeply than words can express. 'To everyone who has supported our family—particularly the emergency services and those who went above and beyond—please accept our sincerest gratitude. 'As we take time to process this tragedy, we kindly ask for privacy and space, knowing your continued support surrounds us.' Richard Crozier, 80 , a friend of the family told the Sun it was a 'terrible tragedy', adding: 'Nischay was a special person. He had a capacity for friendship across generations. 'He wasn't a boy of great numbers of words but he was a very tender-hearted lad.' Flowers and cards have been left at the scene by locals and wellwishers.
The Sun
12 hours ago
- The Sun
Heartbreak as schoolboy, 14, who died while swimming in river is pictured – with parents telling of ‘unimaginable loss'
THE devastated parents of a 14-year-old boy who died while swimming in a river have paid heartfelt tribute to him. Police scrambled to Beccles Quay, off Fen Lane, in Suffolk, just before 7.30pm on Wednesday after concerns for the safety of a teenager in the water. 3 3 The schoolboy had entered the River Waveney with friends but had not resurfaced, said cops. Despite the efforts of onlookers, emergency services and of members of the public, the youngster - named locally as Nischay Patel - tragically died at the scene. Ketan and Praptiben Patel, owners of Tabers Newsagents in Beccles, have now paid tribute to their son Nischay in a Facebook post following the tragedy. Their heartbreaking statement read: "We are deeply grateful to the Police, Suffolk Fire & Rescue Service, East of England Ambulance Service, and HM Coastguard for their swift and compassionate response during this incredibly painful time. "Our heartfelt thanks also go out to the wonderful people of Beccles and those from across the country who have shown us so much kindness, love, and support. "The outpouring of sympathy—from kind words and beautiful flowers to thoughtful gestures—has brought immense comfort to our family. "We would especially like to thank Sir John Leman High School, Thirst Youth Hub, the Beccles Community UK Facebook page, and the local newspapers for their continued support and compassion. "This loss is unimaginable, and as we grieve, we hold close the love of our friends, family, and customers. "Your compassion has touched our hearts more deeply than words can express. "To everyone who has supported our family—particularly the emergency services and those who went above and beyond—please accept our sincerest gratitude. "As we take time to process this tragedy, we kindly ask for privacy and space, knowing your continued support surrounds us." His death has devastated the town, with dozens of flowers and cards left both at the quay and outside the family shop. Richard Crozier, 80, a friend of the family who runs a neighbouring shop, said it had been a "terrible tragedy". 'Nischay was a special person. He had a capacity for friendship across generations," he told Eastern Daily Press. 'He wasn't a boy of great numbers of words but he was a very tender-hearted lad.' Barry Darch, mayor of Beccles, said: 'Beccles is a tight knit community and I'm sure the whole town is in grief.' 3
Yahoo
21-02-2025
- Business
- Yahoo
GSK's Sluggish Shares Seen at Risk of New Activist Campaign
(Bloomberg) -- GSK Plc is a long-term underperformer among Europe's Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist investors again. Trump to Halt NY Congestion Pricing by Terminating Approval Airbnb Billionaire Offers Pre-Fab Homes for LA Fire Victims Sorry, Kids: Disney's New York Headquarters Is for Grown-Ups Trump Targets $128 Billion California High-Speed Rail Project Child Migrant Watchdog Gutted in DOGE Cuts Shares in the British drugmaker have fallen about 19% since it spun off its consumer health business in 2022, a move that activists had supported. Analyst sentiment has been turning more negative, as patents for medicines including HIV treatment dolutegravir are set to expire in coming years. GSK said this month that it's making progress in late-stage development of several oncology drugs, though vaccine sales are falling. 'There needs to be material progress on the pipeline or successful M&A to help address the chronic long-term underperformance of the share price,' said Ketan Patel, fund manager at the family office Whitefriars. In the meantime, 'activist investors will be knocking on the front door.' GSK previously came under pressure from activists Elliott Investment Management and Bluebell Capital Partners. While both broadly agreed with the company's plans to spin off its consumer-health unit, they questioned whether Chief Executive Officer Emma Walmsley was the right leader for GSK. Even so, she has remained at the helm. During Walmsley's near eight-year tenure, GSK shares have delivered a total annualized return of about 3%, compared with more than 7% for peers, according to data compiled by Bloomberg. GSK has also trailed the UK's benchmark FTSE 100 Index during this time, while AstraZeneca Plc has gone on to become the UK's biggest company by market value. 'We believe the current situation at GSK is ripe for an activist to shake up the business given the chronic underperformance compared to chief rival AstraZeneca,' said Emmanuel Valavanis, senior vice president of equity sales at Forte Securities. That could take the form of M&A, a carve out of the vaccines business or a push for more shareholder returns, he said. Dominic Rose, an analyst at Intron Health, also sees shareholder activism as a possibility given GSK's share-price underperformance. 'If activists were to step in, they might push for a sharper strategic focus — potentially advocating for a pure-play vaccines business,' he said. Rose also highlighted operational efficiencies, pipeline acceleration, or capital allocation adjustments as other potential angles. According to David Redfern, president of corporate development at GSK, shareholders 'are very aligned' with what the drugmaker is doing. 'We're pretty focused around building a bigger specialty business, we're focused around our main product areas,' Redfern said in an interview. 'I think all of that is supported — they really just want to see ongoing execution.' The looming patent expiries and concerns about vaccine sales have kept analysts fairly cautious on the stock. GSK's consensus analyst rating — a proxy for the ratio of buy, hold, and sell recommendations — is currently at 3.27, according to data compiled by Bloomberg. That's the lowest score in more than five years, and less than all other major European pharmaceutical companies. Not all analysts are gloomy on GSK. Redburn Atlantic's Simon Baker increased his price target on the stock to 2,650 pence this week, the highest among those tracked by Bloomberg, after the company boosted its 2031 sales forecast to over £40 billion ($51 billion) earlier this month. While that announcement and a buyback plan led to a rally in the stock, those gains have mostly faded since since. GSK shares fell as much as 3.1% to 1,402.5 pence on Friday morning. GSK's new forecast is up from the more than £33 billion it had predicted in 2021. The firm is optimistic about generating sales from drugs it has in development, as well as the potential re-launch of its blood cancer drug Blenrep this year. The shares have also been under pressure in recent years because of ongoing litigation over GSK's old reflux medication, Zantac. The company agreed last year to pay as much as $2.2 billion to resolve the vast majority of court cases. All of this has left GSK trading relatively cheaply. The stock's multiple of about 8.4 times estimated earnings compares with AstraZeneca at about 16 times and is roughly half that of the Stoxx 600 Health Care Index. GSK is 'cheap but challenges persist,' Sarita Kapila, an analyst at Morgan Stanley, wrote in a recent note. The valuation largely reflects longer-term growth challenges, as well as 'the lack of innovation momentum in 2025.' Despite the pessimism, GSK continues to attract investors looking for steady capital returns. The drugmaker's 12-month dividend yield is the highest among peers, while the £2 billion buyback announced this month is the company's first stock repurchase program in more than a decade. Another positive is specialty medicines, including cancer and HIV drugs, for which GSK forecasts a low double-digit percentage revenue increase this year. The company's earnings growth continues to look underappreciated, according to Shore Capital analyst Sean Conroy. For Nick Kirrage, a fund manager at Schroders Plc, GSK has done 'really good work' in terms of restructuring its business. 'They now just have to deliver on the R&D,' he said. 'And I think if you wait five years, they will.' --With assistance from Ashleigh Furlong. (Adds Friday's share price performance.) Japan Perfected 7-Eleven. Why Can't the US Get It Right? How Med Spas Conquered America The Undocumented Workers Who Helped Build Elon Musk's Texas Gigafactory Before DeepSeek Blew Up, Chatbot Arena Announced Its Arrival Elon Musk's DOGE Is a Force Americans Can't Afford to Ignore ©2025 Bloomberg L.P.
